RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

I. F. Tannock, David Osoba, Martin R. Stockler et al. · Journal of Clinical Oncology · 1996 · 1.6K citations

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Francis M. Sirotnak, Maureen F. Zakowski, V.A. Miller et al. · PubMed · 2000 · 761 citations

Immunology, Pharmacotherapy, Human Tumor Xenografts +17

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

Weihua Zhang, Rachel Tsan, Wei‐Chien Huang et al. · Cancer Cell · 2008 · 482 citations · Full text

Tumor Biology, Oncology, Medicine +12

Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

Giuseppe Di Lorenzo, Giampaolo Tortora, Francesco Paolo D’Armiento et al. · PubMed · 2002 · 475 citations

Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas.

Germán Pihán, Jan Wallace, Yening Zhou et al. · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · 2003 · 376 citations · Full text

Tumor Biology, Chromatin, Cell Division +15